Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. announced that its New Drug Application for toripalimab, in combination with cisplatin and gemcitabine, has been approved by the Singapore Health Sciences Authority for the treatment of nasopharyngeal carcinoma (NPC). This approval marks toripalimab as the first immuno-oncology treatment for NPC in Singapore, based on the successful results of the JUPITER-02 Phase III clinical study. The approval is expected to enhance the company’s international market presence and strengthen its position as a leader in the immuno-oncology field.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a Chinese biotechnology company specializing in the development and marketing of innovative drugs, particularly in the field of immuno-oncology. The company focuses on creating monoclonal antibody therapies and has a significant presence in the global market, with its products approved in multiple countries including the United States, European Union, and China.
YTD Price Performance: 19.17%
Average Trading Volume: 1,557,765
Technical Sentiment Signal: Hold
Current Market Cap: HK$26.94B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.